NCT03517488: A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active, untreated, or unstable CNS metastases that require treatment- see trial for details

Comments are closed.

Up ↑